Market Research Logo

Nuclear Medicine/Radiopharmaceutical Global Market – Forecast To 2024

Nuclear Medicine/Radiopharmaceutical Global Market – Forecast To 2024

Over the past 50 years nuclear medicine field has displayed a strong link between investments in chemistry and development of radionuclides and radio-labeled compounds which has impacted the healthcare practice. Nuclear medicine comprises diagnostic and therapeutic techniques that use radioisotopes for applications like oncology, cardiovascular and neurological disorders to provide information at both molecular and cellular level for probing, tracking tissue function, study disease progression and assessing treatment responses.

The nuclear medicine global market is estimated to reach $9,367.8 million by 2024 growing at mid single digit CAGR. Increased radioisotopes applications, rise in public awareness, use of SPECT/CT and PET/CT imaging scans, abundance of radiopharmaceuticals, advancement in imaging technology (hybrid imaging) and alpha therapy based targeted cancer treatment is boosting nuclear medicine market growth. In addition, increasing need in emerging markets, production of radiopharmaceuticals from cyclotrons, efficient diagnosis and treatments, emerging radio isotopes and replacement of old/traditional equipments are the opportunities likely to propel the growth of nuclear medicine market.

Nuclear medicinal market is classified based on modality into diagnosis-therapeutics. Diagnostics market held the largest market revenue in 2017 and is expected grow at single digit CAGR due to increase in SPECT and PET procedures. The therapeutics segment is expected to be the fastest growing segment at high double digit CAGR from 2017 to 2024 due to technological advancements in targeted treatment of cancers. Potential new radioisotopes in pipeline and advancement in neurological treatments are the key factors driving the growth of the therapeutics market. Diagnosis by products is segmented into SPECT and PET. SPECT market held the largest market due to increase in TC-99m isotope applications and product approvals. SPECT is segmented based on isotopes into Technetium (Tc-99m), Thallium (Tl-201), Gallium (Ga-67), Iodine (I-123), Samarium (Sm-153), Yttrium (Y-90), Rhenium (Re-186) and others. Technetium (Tc-99m) accounted for largest share in 2017 and is the fastest growing market with projected single digit CAGR growth during 2017 to 2024 due to increase in approvals of Tc-99m based cold kits for different applications. SPECT market by application is segmented into cardiology, pulmonary, oncology, nephrology, neurology, inflammation, thyroid gland, lymphology and others. Cardiology accounted for largest share in 2017 and remains fastest growing market due to increase in number of cardiac imaging cases using Tc-99m.

PET is the fastest growing segment at mid single digit CAGR from 2017 to 2024 due to increase in adoption of cyclotron for production of PET isotopes increasing its availability. The PET isotopes include Fluorodeoxyglucose (18F-FDG), Gallium (Ga-68), Rubidium (Rb-82) and others. The Fluorodeoxyglucose (18F-FDG) accounted for the largest share in 2017and remains the fastest growing market from 2017 to 2024 due to increase in application related to neurology, bone scan, infection and inflammation. PET by applications is segmented into cardiology, oncology, neurology, inflammation and others. Oncology accounted for largest share in 2017 and is the fastest growing market projected to grow with mid single CAGR from 2017 to 2024 due to increase in patient pool of lung cancer, thyroid cancer and breast cancer.

Therapeutic nuclear medicine market is segmented based on radiation type into alpha radiation, beta radiation and brachytherapy. Alpha radiation accounted largest share in 2017 and is the fastest growing market with projected high double digit CAGR from 2017 to 2024 due to new approval of Ra-223 based cold kits by FDA and other regulatory agencies. Beta radiation therapy by isotopes is further segmented into Y-90, I-131, Lu-177, Sm-153, Re-186, Sr-89, Er-169 and others. I-131 held the largest share and is expected to grow at mid single digit CAGR from 2017 to 2024 due to increased use in treatment of thyroid cancer cases. Lu-177 segment was the fastest growing segment at high single digit CAGR from 2017 to 2024 due to increase in approval of Lu-177 based radiopharmaceuticals for treatment of neuroendocrine tumor. Brachytherapy isotopes are further segmented into I-125, Cs-131, Ir-192, Pd-103 and others. I-125 market accounted the largest share in 2017 and is the fastest growing market with projected CAGR of 3.7% from 2017 to 2024 due to increase in increased use in treatment of lung cancer, prostate cancer, eye related disease (retinoblastoma and eye plaque) and brain cancer. Therapeutic nuclear medicine by application is segmented into prostate cancer, thyroid cancer, liver cancer, gastro-entero-pancreatic-neuroendocrine tumors, metastatic bone cancer, breast cancer and others. Prostate cancer market accounted the largest share in 2017 and is the fastest growing market projected with double digit CAGR growth from 2017 to 2024 due to increase in increased use in treatment of prostate cancer.

Nuclear medicine based on end-user is segmented into hospitals, ambulatory centers, diagnostic centers and others. Hospital accounted the largest share in 2017 and is the fastest growing market projected with CAGR of 7.2% from 2017 to 2024 due to readily availability of cyclotrons for generation of isotope and use of advanced hybrid imaging.

The stable isotope global market is poised to reach $256.9 million by 2024. The Nuclear Medicine market includes stable isotopes which are classified into isotopes and applications. Isotopes considered are carbon (C-13), deuterium (D2), oxygen (O-18), nitrogen (N-15), Sulphur (S-32) and others. Deuterium (D-2) accounted largest share in 2017 and is the fastest growing market with projected low single digit CAGR growth from 2017 to 2024 due to use of deuterium as dietary supplement of deuterium-depleted water which helps to extend survival rate of lung cancer patient via exerting anticancer effect and modification of deuterium leads to development of novel, highly differentiated drugs which have therapeutic applications in diabetic nephropathy, hot flashes, spasticity, neuropathic pain and multiple melanoma. The stable isotope applications market is segmented into diagnostics-therapy, pharmaceutical companies and others. Diagnostics-therapy market commanded the largest market revenue in 2017 and expected to grow at a CAGR of 2.6% due to use in diagnosis and treatment of pancreas, liver and intestine related disorders. The pharmaceuticals is projected to be the fastest growing segment from 2017 to 2024 due to novel developments in utilization of stable isotopes which involve biopolymers, where isotope-labeled species are generated from cells grown on labeled growth media.

Geographical wise, North America is the largest market, with a significant share followed by Europe, Asia-Pacific and Rest of the World. North American region commanded the largest revenue market and expected to grow at mid single digit CAGR. Growing use of SPECT and PET scans, technological advancements in equipment, increased utilization of fusion imaging, alpha radio immunotherapy based targeted cancer treatment and complete availability of radiopharmaceutical has led the market growth in this region. However, Asia-Pacific region is expected to grow at a high single digit CAGR from 2017 to 2024 due to increased public awareness and increase in application.

The nuclear medicine global market is a competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares and also acquiring small companies for product expansion. Some of the key players of the nuclear medicine market are Curium Pharma (France), Bayer AG (Germany), GE Company (U.S.), Cardinal Health (U.S.), Jubilant Life science (India), Lantheus Medical Imaging (U.S.), Novartis International AG (Advanced accelerator) (Switzerland), South African Nuclear Energy Corporation (NTP Radioisotopes SOC Ltd) (South Africa), Siemens AG (Germany) and Fujifilm Holding Corporation (Japan).

The report provides an in depth market analysis of the above mentioned segments across the following regions:

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World (RoW)


1 EXECUTIVE SUMMARY
2 INTRODUCTION
2.1 KEY TAKE AWAYS
2.2 REPORT SCOPE
2.3 REPORT DESCRIPTION
2.4 MARKETS COVERED
2.5 STAKEHOLDERS
2.6 RESEARCH METHODOLOGY
2.6.1 MARKET SIZE ESTIMATION
2.6.2 MARKET CRACKDOWN AND DATA TRIANGULATION
2.6.3 SECONDARY SOURCES
2.6.4 PRIMARY SOURCES
2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES
2.6.7 KEY DATA POINTS FROM PRIMARY SOURCES
2.6.8 ASSUMPTIONS
3 MARKET ANALYSIS
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
3.3.1 DRIVERS AND OPPORTUNITIES
3.3.1.1 Increased applications of Radiopharmaceuticals
3.3.1.2 Rise in public awareness
3.3.1.3 Usage of hybrid imaging
3.3.1.4 Technological advancements
3.3.1.5 Increasing needs in emerging markets
3.3.1.6 Production of Radiopharmaceuticals from Cyclotrons
3.3.1.7 Efficient diagnosis and treatments
3.3.2 RESTRAINTS AND THREATS
3.3.2.1 Shorter half-life of Radiopharmaceuticals
3.3.2.2 High cost and supply shortage of isotopes
3.3.2.3 Radio toxicity
3.3.2.4 Shortage of qualified technicians
3.3.2.5 Regulatory Issues
3.3.2.6 Threat from traditional/alternative diagnostic procedures
3.3.2.7 Huge Capital Investment
3.4 PROBLEM AREAS
3.4.1 CLOSURE OF REACTORS
3.5 WINNING IMPERATIVES
3.5.1 AVAILABILITY OF TECHNETIUM
3.6 REGULATORY GUIDELINES
3.6.1 UNITED STATES
3.6.2 EUROPE
3.6.3 JAPAN
3.6.4 INDIA
3.6.5 CHINA
3.6.6 SOUTH KOREA
3.7 REIMBURSEMENT SCENARIO AND CHALLENGES
3.8 CLINICAL TRIALS
3.9 PATENT TRENDS
3.10 SUPPLY CHAIN ANALYSIS
3.10.1 REACTORS
3.10.2 PROCESSING FACILITY
3.10.3 GENERATORS MANUFACTURING UNITS
3.10.4 HOSPITALS AND CENTRAL RADIO PHARMACIES
3.11 LIST OF POTENTIAL NEW REACTORS
3.12 LIST OF FDA APROVED RADIOPHARMACEUTICALS
3.13 PORTER'S FIVE FORCE ANALYSIS
3.13.1 THREAT OF NEW ENTRANTS
3.13.2 THREAT OF SUBSTITUTES
3.13.3 BARGAINING POWER OF SUPPLIERS
3.13.4 BARGAINING POWER OF BUYERS
3.13.5 COMPETITIVE RIVALRY
3.14 MARKET SHARE ANALYSIS BY MAJOR PLAYERS
3.14.1 NUCLEAR MEDICINE MARKET
3.14.2 SPECT MARKET
3.14.3 PET MARKET
3.14.4 TC-99 MARKET
4 NUCLEAR MEDICINE GLOBAL MARKET, BY MODALITY
4.1 INTRODUCTION
4.2 DIAGNOSTICS
4.2.1 RADIOPHARMACEUTICALS FOR DIAGNOSIS, BY ISOTOPES
4.2.1.1 SPECT, by Isotopes
4.2.1.1.1 Technetium (Tc-99m)
4.2.1.1.2 Thallium (Tl-201)
4.2.1.1.3 Gallium (Ga-67)
4.2.1.1.4 Iodine (I-123)
4.2.1.1.5 Samarium (Sm-153)
4.2.1.1.6 Yttrium (Y-90)
4.2.1.1.7 Rhenium (Re-186)
4.2.1.1.8 Others
4.2.1.2 PET, by Isotopes
4.2.1.2.1 Fluorodeoxyglucose (18F-FDG)
4.2.1.2.2 Gallium (Ga-68)
4.2.1.2.3 Rubidium (Rb-82)
4.2.1.2.4 Others
4.2.2 NUCLEAR MEDICINE FOR DIAGNOSIS, BY APPLICATION
4.2.2.1 SPECT by Application
4.2.2.1.1 Cardiology
4.2.2.1.2 Pulmonary
4.2.2.1.3 Oncology
4.2.2.1.4 Nephrology
4.2.2.1.5 Neurology
4.2.2.1.6 Inflammation
4.2.2.1.7 Thyroid glands
4.2.2.1.8 Lymphology
4.2.2.1.9 Others
4.2.2.2 PET by Application
4.2.2.2.1 Oncology
4.2.2.2.2 Neurology
4.2.2.2.3 Cardiology
4.2.2.2.4 Inflammation
4.2.2.2.5 Others
4.3 THERAPEUTICS
4.3.1 NUCLEAR MEDICINE FOR THERAPEUTICS, BY RADIATION TYPE
4.3.1.1 Beta radiation Therapy
4.3.1.1.1 Yttrium (Y-90)
4.3.1.1.2 Iodine (I-131)
4.3.1.1.3 Lutetium (Lu-177)
4.3.1.1.4 Samarium (Sm-153)
4.3.1.1.5 Rhenium (Re-186)
4.3.1.1.6 Strontium (Sr-89)
4.3.1.1.7 Erbium (Er-169)
4.3.1.1.8 Others
4.3.1.2 Alpha radiation therapy, by isotopes
4.3.1.3 Brachytherapy, by Isotopes
4.3.1.3.1 Iodine (I-125)
4.3.1.3.2 Cesium (Cs-131)
4.3.1.3.3 Iridium (Ir-192)
4.3.1.3.4 Palladium (Pd-103)
4.3.1.3.5 Others
4.3.2 NUCLEAR MEDICINE THERAPEUTICS, BY APPLICATION
4.3.2.1 Prostate cancer
4.3.2.2 Thyroid cancer
4.3.2.3 Liver cancer
4.3.2.4 GEP-NET Therapeutics
4.3.2.5 Metastatic Bone Cancer Therapeutics
4.3.2.6 Breast Cancer Therapeutics
4.3.2.7 Other Therapeutic Applications
5 NUCLEAR MEDICINE GLOBAL MARKET, BY END-USERS
5.1 INTRODUCTION
5.2 HOSPITAL
5.3 AMBULATOR-Y CENTERS
5.4 DIAGNOSTIC CENTERS
5.5 OTHER END-USERS
6 STABLE ISOTOPES
6.1 INTRODUCTION
6.2 MARKET ANALYSIS
6.2.1 FACTORS INFLUENCING MARKET
6.2.2 DRIVERS AND OPPORTUNITIES
6.2.2.1 Increase in research activities (Pharmaceuticals and biotechnology sectors)
6.2.2.2 Increasing applications
6.2.3 RESTRAINTS AND THREATS
6.2.3.1 High cost of stable isotopes
6.2.3.2 Stable isotopes-side effects and safety issues
6.2.3.3 Stringent Regulations for manufacturing and use of stable isotopes
6.3 STABLE ISOTOPES MARKET, BY ISOTOPE
6.3.1 Carbon (C-13)
6.3.2 Deuterium (D2)
6.3.3 Oxygen (O-18)
6.3.4 Nitrogen (N-15)
6.3.5 Sulphur (S-32)
6.3.6 Others
6.4 STABLE ISOTOPES MARKET, BY APPLICATION
6.4.1 INTRODUCTION
6.4.2 DIAGNOSTICS AND THERAPY
6.4.3 PHARMACEUTICALS
6.4.4 OTHERS
6.5 STABLE ISOTOPES MARKET, BY GEOGRAPHY
6.5.1 INTRODUCTION
6.5.2 NORTH AMERICA
6.5.3 EUROPE
6.5.4 ASIA-PACIFIC
6.5.5 REST OF THE WORLD
7 REGIONAL ANALYSIS
7.1 INTRODUCTION
7.2 NORTH AMERICA
7.2.1 U.S.
7.2.2 OTHERS
7.3 EUROPE
7.3.1 GERMANY
7.3.2 FRANCE
7.3.3 ITALY
7.3.4 OTHERS
7.4 ASIA-PACIFIC
7.4.1 JAPAN
7.4.2 CHINA
7.4.3 AUSTRALIA
7.4.4 OTHERS
7.5 REST OF THE WORLD
7.5.1 BRAZIL
7.5.2 REST OF LATIN AMERICA
7.5.3 MIDDLE EAST AND SOUTH AFRICA
8 COMPETITIVE LANDSCAPE
8.1 INTRODUCTION
8.2 APPROVALS AND AGREEMENTS
8.3 ACQUISITION, EXPANSION AND COLLABORATION
8.4 OTHERS DEVELOPMENTS
9 MAJOR PLAYER PROFILES
9.1 ADVANCE ACCELERATOR APPLICATIONS SA (NOVARTIS)
9.1.1 OVERVIEW
9.1.2 FINANCIALS
9.1.3 PRODUCT PORTFOLIO
9.1.4 KEY DEVELOPMENTS
9.1.5 BUSINESS STRATEGY
9.1.6 SWOT ANALYSIS
9.2 AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION
(ANSTO)
9.2.1 OVERVIEW
9.2.2 FINANCIALS
9.2.3 PRODUCT PORTFOLIO
9.2.4 KEY DEVELOPMENTS
9.2.5 BUSINESS STRATEGY
9.2.6 SWOT ANALYSIS
9.3 BAYER GROUP
9.3.1 OVERVIEW
9.3.2 FINANCIALS
9.3.3 PRODUCT PORTFOLIO
9.3.4 KEY DEVELOPMENTS
9.3.5 BUSINESS STRATEGY
9.3.6 SWOT ANALYSIS
9.4 CARDINAL HEALTH INC.
9.4.1 OVERVIEW
9.4.2 FINANCIALS
9.4.3 PRODUCT PORTFOLIO
9.4.4 KEY DEVELOPMENTS
9.4.5 BUSINESS STRATEGY
9.4.6 SWOT ANALYSIS
9.5 CURIUM PHARMA
9.5.1 OVERVIEW
9.5.2 FINANCIALS
9.5.3 PRODUCT PORTFOLIO
9.5.4 KEY DEVELOPMENTS
9.5.5 BUSINESS SRATEGY
9.5.6 SWOT ANALYSIS
9.6 FUJIFILM HOLDINGS CORPORATION
9.6.1 OVERVIEW
9.6.2 FINANCIALS
9.6.3 PRODUCT PORTFOLIO
9.6.4 KEY DEVELOPMENTS
9.6.5 BUSINESS SRATEGY
9.6.6 SWOT ANALYSIS
9.7 GE COMPANY (GE HEALTHCARE)
9.7.1 OVERVIEW
9.7.2 FINANCIALS
9.7.3 PRODUCT PORTFOLIO
9.7.4 KEY DEVELOPMENTS
9.7.5 BUSINESS SRATEGY
9.7.6 SWOT ANALYSIS
9.8 JUBILANT LIFESCIENCE
9.8.1 OVERVIEW
9.8.2 FINANCIALS
9.8.3 PRODUCT PORTFOLIO
9.8.4 KEY DEVELOPMENTS
9.8.5 BUSINESS SRATEGY
9.8.6 SWOT ANALYSIS
9.9 LANTHEUS MEDICAL IMAGING INC.
9.9.1 OVERVIEW
9.9.2 FINANCIALS
9.9.3 PRODUCT PORTFOLIO
9.9.4 KEY DEVELOPMENTS
9.9.5 BUSINESS STRATEGY
9.9.6 SWOT ANALYSIS
9.10 SOTERA HEALTH LLC (NORDION INC)
9.10.1 OVERVIEW
9.10.2 FINANCIALS
9.10.3 PRODUCT PORTFOLIO
9.10.4 KEY DEVELOPMENTS
9.10.5 BUSINESS STRATEGY
9.10.6 SWOT ANALYSIS
9.11 SOUTH AFRICAN NUCLEAR ENERGY CORPORATION (NECSA)
(NTP RADIOISOTOPES SOC LTD)
9.11.1 OVERVIEW
9.11.2 FINANCIALS
9.11.3 PRODUCT PORTFOLIO
9.11.4 KEY DEVELOPMENTS
9.11.5 BUSINESS STRATEGY
9.11.6 SWOT ANALYSIS
9.12 SIEMENS AG
9.12.1 OVERVIEW
9.12.2 FINANCIALS
9.12.3 PRODUCT PORTFOLIO
9.12.4 KEY DEVELOPMENTS
9.12.5 BUSINESS STRATEGY
9.12.6 SWOT ANALYSIS
LIST OF TABLES
TABLE 1 NUCLEAR MEDICINE GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 2 RADIOPHARMACUTICALS THAT WILL CONTINUE TO RECEIVE PASS THROUGH STATUS
TABLE 3 REIMBURSEMENT RATES FOR RADIOPHARMACEUTICALS AND DIAGNOSTIC IMAGING TECHNIQUES
TABLE 4 TECHNETIUM (TC-99M) REACTORS
TABLE 5 NEW POTENTIAL REACTORS
TABLE 6 FDA APPROVED RADIOPHARMACEUTICALS
TABLE 7 NUCLEAR MEDICINE GLOBAL MARKET REVENUE,
BY MODALITY, (2016-2024) ($MN)
TABLE 8 NUCLEAR MEDICINE DIAGNOSTICS GLOBAL MARKET REVENUE,
BY PRODUCTS, (2016-2024) ($MN)
TABLE 9 NUCLEAR MEDICINE DIAGNOSTIC GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 10 NUCLEAR MEDICINE SPECT GLOBAL MARKET REVENUE,
BY ISOTOPE, (2016-2024) ($MN)
TABLE 11 NUCLEAR MEDICINE SPECT GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 12 TECHNETIUM (Tc-99m) ISOTOPE GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 13 THALLIUM (Tl-201) ISOTOPE GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 14 GALLIUM (Ga-67) ISOTOPE GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 15 IODINE (I-123) ISOTOPE GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 16 SAMARIUM (Sm-153) ISOTOPE GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 17 YTTRIUM (Y-90) ISOTOPE GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 18 RHENIUM (Re-186) ISOTOPE GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 19 OTHER ISOTOPES GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 20 NUCLEAR MEDICINE PET GLOBAL MARKET REVENUE,
BY ISOTOPES, (2016-2024) ($MN)
TABLE 21 NUCLEAR MEDICINE PET GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 22 FLUORODEOXYGLUCOSE (18F-FDG) GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 23 GALLIUM (Ga-68) ISOTOPE GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 24 RUBIDIUM (Rb-82) ISOTOPE GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 25 OTHER PET ISOTOPES GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 26 NUCLEAR MEDICINE SPECT GLOBAL MARKET REVENUE,
BY APPLICATION, (2016-2024) ($MN)
TABLE 27 CARDIOLOGY GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 28 PULMONARY GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 29 ONCOLOGY GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 30 NEPHROLOGY GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 31 NEUROLOGY GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 32 INFLAMMATION GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 33 THYROID GLANDS GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 34 LYMPHOLOGY SPECT GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 35 OTHER APPLICATIONS GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 36 NUCLEAR MEDICINE PET GLOBAL MARKET REVENUE,
BY APPLICATION, (2016-2024) ($MN)
TABLE 37 ONCOLOGY GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 38 NEUROLOGY GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 39 CARDIOLOGY GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 40 INFLAMMATION GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 41 OTHERS GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 42 NUCLEAR MEDICINE THERAPEUTICS GLOBAL MARKET REVENUE,
BY RADIATION TYPE, (2016-2024) ($MN)
TABLE 43 NUCLEAR MEDICINE THERAPEUTICS GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 44 BETA RADIATION THERAPY GLOBAL MARKET REVENUE,
BY ISOTOPES, (2016-2024) ($MN)
TABLE 45 BETA RADIATION THERAPY GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 46 YTTRIUM (Y-90) ISOTOPE GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 47 IODINE(I-131) ISOTOPE GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 48 LUTETIUM (Lu-177) ISOTOPE GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 49 SAMARIUM (Sm-153) ISOTOPE GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 50 RHENIUM (Re-186) ISOTOPE GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 51 STRONTIUM (Sr-89) ISOTOPE GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 52 ERBIUM (Er-169) ISOTOPE GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 53 OTHER ISOTOPES GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 54 ALPHA RADIATION THERAPY GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 55 BRACHYTHERAPY GLOBAL MARKET REVENUE,
BY ISOTOPES, (2016-2024) ($MN)
TABLE 56 BRACHYTHERAPY GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 57 IODINE (I-125) ISOTOPE GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 58 CESIUM (Cs-131) ISOTOPE GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 59 IRIDIUM (Ir-192) ISOTOPE GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 60 PALLADIUM (Pd-103) ISOTOPE GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 61 OTHER ISOTOPES GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 62 NUCLEAR MEDICINE THERAPEUTICS GLOBAL MARKET REVENUE,
BY APPLICATION, (2016-2024) ($MN)
TABLE 63 PROSTATE CANCER GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 64 THYROID CANCER GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 65 LIVER CANCER GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 66 GEP-NET GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 67 METASTATIC BONE CANCER GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
TABLE 68 BREAST CANCER GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 69 OTHER THERAPEUTIC APPLICATIONS GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 70 NUCLEAR MEDICINE GLOBAL MARKET REVENUE,
BY END-USERS, (2016-2024) ($MN)
TABLE 71 HOSPITAL GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 72 AMBULATORY CENTERS GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
TABLE 73 DIAGNOSTIC CENTRES END-USER GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 74 OTHER END-USER GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 75 STABLE ISOTOPES GLOBAL MARKET REVENUE,
BY ISOTOPE, (2016-2024) ($MN)
TABLE 76 STABLE ISOTOPES GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 77 CARBON (C-13) GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 78 DEUTERIUM (D2) GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 79 OXYGEN (O-18) ISOTOPE GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 80 NITROGEN (N-15) ISOTOPE GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 81 SULPHUR (S-32) ISOTOPE GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 82 OTHER STABLE ISOTOPES GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 83 STABLE ISOTOPES GLOBAL MARKET REVENUE,
BY APPLICATION, (2016-2024) ($MN)
TABLE 84 DIAGNOSTICS-THERAPY APPLICATION GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 85 PHARMACEUTICALS GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 86 OTHERS GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 87 STABLE ISOTOPES GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 88 NORTH AMERICA STABLE ISOTOPES MARKET REVENUE,
BY ISOTOPE, (2016-2024) ($MN)
TABLE 89 NORTH AMERICA STABLE ISOTOPES MARKET REVENUE,
BY APPLICATION, (2016-2024) ($MN)
TABLE 90 EUROPE STABLE ISOTOPES MARKET REVENUE,
BY ISOTOPE, (2016-2024) ($MN)
TABLE 91 EUROPE STABLE ISOTOPES MARKET REVENUE,
BY APPLICATION, (2016 -2024) ($MN)
TABLE 92 ASIA-PACIFIC STABLE ISOTOPES MARKET REVENUE,
BY ISOTOPE, (2016-2024) ($MN)
TABLE 93 ASIA-PACIFIC STABLE ISOTOPES MARKET REVENUE,
BY APPLICATION, (2016-2024) ($MN)
TABLE 94 REST OF THE WORLD STABLE ISOTOPES MARKET REVENUE,
BY ISOTOPE, (2016-2024) ($MN)
TABLE 95 REST OF THE WORLD STABLE ISOTOPES MARKET REVENUE,
BY APPLICATION, (2016-2024) ($MN)
TABLE 96 NUCLEAR MEDICINE GLOBAL MARKET REVENUE,
BY REGION, (2016-2024) ($MN)
TABLE 97 NORTH AMERICA NUCLEAR MEDICINE MARKET REVENUE,
BY MODALITY, (2016-2024) ($MN)
TABLE 98 NORTH AMERICA NUCLEAR MEDICINE DIAGNOSTICS MARKET REVENUE,
BY PRODUCTS, (2016-2024) ($MN)
TABLE 99 NORTH AMERICA NUCLEAR MEDICINE SPECT MARKET REVENUE,
BY ISOTOPE, (2016-2024) ($MN)
TABLE 100 NORTH AMERICA NUCLEAR MEDICINE PET MARKET REVENUE,
BY ISOTOPE, (2016-2024) ($MN)
TABLE 101 NORTH AMERICA NUCLEAR MEDICINE SPECT MARKET REVENUE,
BY APPLICATION, (2016-2024) ($MN)
TABLE 102 NORTH AMERICA NUCLEAR MEDICINE PET MARKET REVENUE,
BY APPLICATION, (2016-2024) ($MN)
TABLE 103 NORTH AMERICA NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BY RADIATION TYPE, (2016-2024) ($MN)
TABLE 104 NORTH AMERICA NUCLEAR MEDICINE BETA RADIATION THERAPY MARKET REVENUE, BY ISOTOPE, (2016-2024) ($MN)
TABLE 105 NORTH AMERICA NUCLEAR MEDICINE BRACHYTHERAPY MARKET REVENUE, BY ISOTOPE, (2016-2024) ($MN)
TABLE 106 NORTH AMERICA NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BY APPLICATION, (2016-2024) ($MN)
TABLE 107 NORTH AMERICA NUCLEAR MEDICINE MARKET REVENUE,
BY END-USERS, (2016-2024) ($MN)
TABLE 108 NORTH AMERICA NUCLEAR MEDICINE MARKET REVENUE,
BY COUNTRY, (2016-2024) ($MN)
TABLE 109 EUROPE NUCLEAR MEDICINE MARKET REVENUE,
BY MODALITY, (2016-2024) ($MN)
TABLE 110 EUROPE NUCLEAR MEDICINE DIAGNOSTICS MARKET REVENUE,
BY PRODUCTS, (2016-2024) ($MN)
TABLE 111 EUROPE NUCLEAR MEDICINE SPECT MARKET REVENUE,
BY ISOTOPE, (2016-2024) ($MN)
TABLE 112 EUROPE NUCLEAR MEDICINE PET MARKET REVENUE,
BY ISOTOPE, (2016-2024) ($MN)
TABLE 113 EUROPE NUCLEAR MEDICINE SPECT MARKET REVENUE,
BY APPLICATION, (2016-2024) ($MN)
TABLE 114 EUROPE NUCLEAR MEDICINE PET MARKET REVENUE,
BY APPLICATION, (2016-2024) ($MN)
TABLE 115 EUROPE NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE,
BY RADIATION TYPE, (2016-2024) ($MN)
TABLE 116 EUROPE NUCLEAR MEDICINE BETA RADIATION THERAPY MARKET REVENUE, BY ISOTOPE, (2016-2024) ($MN)
TABLE 117 EUROPE NUCLEAR MEDICINE BRACHYTHERAPY MARKET REVENUE,
BY ISOTOPE, (2016-2024) ($MN)
TABLE 118 EUROPE NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE,
BY APPLICATION, (2016-2024) ($MN)
TABLE 119 EUROPE NUCLEAR MEDICINE MARKET REVENUE,
BY END-USERS, (2016-2024) ($MN)
TABLE 120 EUROPE NUCLEAR MEDICINE MARKET REVENUE,
BY COUNTRY, (2016-2024) ($MN)
TABLE 121 ASIA-PACIFIC NUCLEAR MEDICINE MARKET REVENUE,
BY MODALITY, (2016-2024) ($MN)
TABLE 122 ASIA-PACIFIC NUCLEAR MEDICINE DIAGNOSTICS MARKET REVENUE,
BY PRODUCTS, (2016-2027) ($MN)
TABLE 123 ASIA-PACIFIC NUCLEAR MEDICINE SPECT MARKET REVENUE,
BY ISOTOPE, (2016-2024) ($MN)
TABLE 124 ASIA-PACIFIC NUCLEAR MEDICINE PET MARKET REVENUE,
BY ISOTOPE, (2016-2024) ($MN)
TABLE 125 ASIA-PACIFIC NUCLEAR MEDICINE SPECT MARKET REVENUE,
BY APPLICATION, (2016-2024) ($MN)
TABLE 126 ASIA-PACIFIC NUCLEAR MEDICINE PET MARKET REVENUE,
BY APPLICATION, (2016-2024) ($MN)
TABLE 127 ASIA-PACIFIC NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE,
BY RADIATION TYPE, (2016-2024) ($MN)
TABLE 128 ASIA-PACIFIC NUCLEAR MEDICINE BETA RADIATION THERAPY MARKET REVENUE, BY ISOTOPE, (2016-2024) ($MN)
TABLE 129 ASIA-PACIFIC NUCLEAR MEDICINE BRACHYTHERAPY MARKET REVENUE,
BY ISOTOPE, (2016-2024) ($MN)
TABLE 130 ASIA-PACIFIC NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE,
BY APPLICATION, (2016-2024) ($MN)
TABLE 131 ASIA-PACIFIC NUCLEAR MEDICINE MARKET REVENUE,
BY END-USERS, (2016-2024) ($MN)
TABLE 132 ASIA-PACIFIC NUCLEAR MEDICINE MARKET REVENUE,
BY COUNTRY, (2016-2024) ($MN)
TABLE 133 REST OF THE WORLD NUCLEAR MEDICINE MARKET REVENUE,
BY MODALITY, (2016-2024) ($MN)
TABLE 134 REST OF THE WORLD NUCLEAR MEDICINE DIAGNOSTICS MARKET REVENUE, BY PRODUCTS, (2016-2024) ($MN)
TABLE 135 REST OF THE WORLD NUCLEAR MEDICINE SPECT MARKET REVENUE,
BY ISOTOPE, (2016-2024) ($MN)
TABLE 136 REST OF THE WORLD NUCLEAR MEDICINE PET MARKET REVENUE,
BY ISOTOPE, (2016-2024) ($MN)
TABLE 137 REST OF THE WORLD NUCLEAR MEDICINE SPECT MARKET REVENUE,
BY APPLICATION, (2016-2024) ($MN)
TABLE 138 REST OF THE WORLD NUCLEAR MEDICINE PET MARKET REVENUE,
BY APPLICATION, (2016-2024) ($MN)
TABLE 139 REST OF THE WORLD NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BY RADIATION TYPE, (2016-2024) ($MN)
TABLE 140 REST OF THE WORLD NUCLEAR MEDICINE BETA RADIATION THERAPY MARKET REVENUE, BY ISOTOPE, (2016-2024) ($MN)
TABLE 141 REST OF THE WORLD NUCLEAR MEDICINE BRACHYTHERAPY MARKET REVENUE, BY ISOTOPE, (2016-2024) ($MN)
TABLE 142 REST OF THE WORLD NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BY APPLICATION, (2016-2024) ($MN)
TABLE 143 REST OF THE WORLD NUCLEAR MEDICINE MARKET REVENUE, BY END-USERS, (2016-2024) ($MN)
TABLE 144 ROW NUCLEAR MEDICINE MARKET REVENUE,
BY COUNTRY, (2016-2024) ($MN)
TABLE 145 APPROVALS AND AGREEMENTS (2016-2018)
TABLE 146 ACQUISITION, EXPANSION AND COLLABORATION, (2016-2018)
TABLE 147 OTHER DEVELOPMENTS (2016-2018)
TABLE 148 ADVANCE ACCELERATOR APPLICATIONS SA: TOTAL REVENUE AND R&D EXPENSES (2015-2017) ($MN)
TABLE 149 ADVANCE ACCELERATOR APPLICATIONS SA: TOTAL REVENUE,
BY SEGMENTS (2015-2017) ($MN)
TABLE 150 ADVANCE ACCELERATOR APPLICATIONS SA: TOTAL REVENUE,
BY GEOGRAPHY (2015-2017) ($MN)
TABLE 151 AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANIZATION:
TOTAL REVENUE AND R&D EXPENSES (2015-2017) ($MN)
TABLE 152 OVERVIEW: BAYER GROUP
TABLE 153 BAYER GROUP: TOTAL REVENUE AND R&D EXPENSES,
(2015-2017) ($MN)
TABLE 154 BAYER GROUP: TOTAL REVENUE, BY SEGMENTS (2015-2017) ($MN)
TABLE 155 BAYER GROUP: TOTAL REVENUE,
BY GEOGRAPHY, (2015-2017) ($MN)
TABLE 156 CARDINAL HEALTH, INC.: TOTAL REVENUE AND R&D EXPENSES
(2016-2018) ($MN)
TABLE 157 CARDINAL HEALTH, INC.: TOTAL REVENUE,
BY SEGMENTS, (2016-2018) ($MN)
TABLE 158 CARDINAL HEALTH, INC.: TOTAL REVENUE,
BY GEOGRAPHY, (2016-2018) ($MN)
TABLE 159 OVERVIEW: FUJIFILM HOLDING CORPORATION
TABLE 160 FUJIFILM HOLDING CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2016 – 2018) ($MN)
TABLE 161 FUJIFILM HOLDING CORPORATION: TOTAL REVENUE,
BY SEGMENTS (2016-2018) ($MN)
TABLE 162 FUJIFILM HOLDING CORPORATION: TOTAL REVENUE,
BY GEOGRAPHY (2016 – 2018) ($BN)
TABLE 163 OVERVIEW: GE COMPANY
TABLE 164 GE COMPANY: TOTAL REVENUE AND R&D EXPENSES
(2015 – 2017) ($MN)
TABLE 165 GE COMPANY: TOTAL REVENUE, BY SEGMENTS (2015-2017) ($MN)
TABLE 166 GE COMPANY: TOTAL REVENUE, BY GEOGRAPHY (2015 – 2017) ($MN)
TABLE 167 JUBILANT LIFESCIENCE: TOTAL REVENUE AND R&D EXPENSES
(2015 – 2017) ($MN)
TABLE 168 JUBILANT LIFESCIENCE: TOTAL REVENUE,
BY SEGMENTS (2015-2017) ($MN)
TABLE 169 JUBILANT LIFESCIENCE: PHARMACEUTICAL TOTAL REVENUE,
BY SEGMENTS (2015-2017) ($MN)
TABLE 170 JUBILANT LIFESCIENCE: SPCEIALTY PHARMACEUTICAL INJECTABLES TOTAL REVENUE, BY SEGMENTS (2015-2017) ($MN)
TABLE 171 JUBILANT LIFESCIENCE: TOTAL REVENUE,
BY GEOGRAPHY (2015 – 2017) ($BN)
TABLE 172 OVERVIEW: LANTHEUS MEDICAL IMAGING INC.
TABLE 173 LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
TABLE 174 LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE,
BY PRODUCTS (2015-2017) ($MN)
TABLE 175 LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE,
BY GEOGRAPHY (2015-2017) ($MN)
TABLE 176 SIEMENS AG: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
TABLE 177 SIEMENS AG: TOTAL REVENUE,
BY SEGMENT, (2015-2017) ($MN)
TABLE 178 SIEMENS AG : TOTAL REVENUE,
BY GEOGRAPHY (2015-2017) ($MN)
LIST OF FIGURES
FIGURE 1 NUCLEAR MEDICINE GLOBAL MARKET SHARE AND REVENUE,
BY REGION, (2016-2024) ($MN)
FIGURE 2 RESEARCH METHODOLOGY: NUCLEAR MEDICINE GLOBAL MARKET
FIGURE 3 NUCLEAR MEDICINE GLOBALMARKET:
TOP-DOWN AND BOTTOM-UP APPROACH
FIGURE 4 NUCLEAR MEDICINE GLOBAL MARKET: FORECASTING MODEL
FIGURE 5 NUCLEAR MEDICINE GLOBAL MARKET: MARKET CRACKDOWN AND DATA TRIANGULATION
FIGURE 6 NUCLEAR MEDICINE GLOBAL MARKET: MARKET SEGMENTATION
FIGURE 7 STABLE ISOTOPES GLOBAL MARKET: MARKET SEGMENTATION
FIGURE 8 MARKET DYNAMICS

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report